Thermo Fisher Scientific Stock News

WASHINGTON, March 07, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Genomics in Cancer Care Market finds that rising demand for technologically advanced & cost-efficient diagnostic technology and increasing demand for diagnostics centres are augmenting the growth of Genomics in Cancer Care Market in upcoming years. In addition, growing research activities for the development of novel treatment therapies and increasing funding for the development of pharmaceutical and biotech industry are some other important parameters that bolstering the market demand in the projected time span. The total Global Genomics in Cancer Care Market is estimated to reach USD 40.5 Billion by 2028. The market stood at a revenue of USD 12.1 Billion in the year 2021, and expected to grow at a Compound Annual Growth Rate (CAGR) of 16.1%, states Vantage Market Research, in a report, titled " Genomics in Cancer Care Market by Product (Instruments, Consumables, Services), by Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), by Technology (Genome Sequencing, PCR, Microarrays, Nucleic Acid Extraction & Purification), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

IHI: A Standout Performer With Equally Strong Future Growth Prospects

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

We think that Thermo Fisher Scientific stock currently is a better pick compared to Abbott Labs stock , with a similar market capitalization in the healthcare sector, despite…

Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry Global Market Report 2022, By Type, By Technology, By End User, By Application" report has been added to ResearchAndMarkets.com''s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global flow cytometry market. The report gives a guide to the flow cytometry market which will be shaping and changing our lives over the next ten years and beyond, including the market''s response to the challenge of the global pandemic Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market.

Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.

We think that Thermo Fisher Scientific stock (NYSE: TMO) currently is a better pick compared to Abbott Labs stock (NYSE: ABT), with a similar market capitalization in the healthcare sector, despite it

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediat

Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services.

We estimate the PPD acquisition to contribute 14% of the company's total revenues in 2022, as well as $25 mln in cost synergies.

Thermo Fisher (TMO) continues to be a trusted partner of Moderna, bringing a wide range of products and services enabling Moderna to deliver innovative medicines at an extraordinary speed and scale.